This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
Purpose
This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
Conditions
- Influenza, Human
- COVID-19
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Enrolled in Optum claims database as of 31 August 2022 (date bivalent authorized). - Has a Pfizer-BioNTech mRNA bivalent COVID-19 or influenza vaccine (any type) between 31 August 2022 and 30 January 2023 (earliest vaccine is index date). - Aged >=18 years on the index date - 365 days of continuous enrolment prior to index date
Exclusion Criteria
- Patients with a second dose of any type of bivalent mRNA COVID-19 or flu vaccine, disenrolled or died within 14 days following the first dose. - Has prior COVID-19 diagnosis (U07.1, any setting, any position) within 90 days (per CDC guidance on length of time before receiving a vaccine) before and on index. - Has influenza vaccine between 01 August -30 August 2022 (before study period). - Has a COVID-19 or influenza diagnosis code in any setting within 14 days after index vaccination (excluded from all cohorts).
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Same day | Pfizer-BioNTech mRNA bivalent COVID and flu on the same day |
|
COVID alone | Pfizer-BioNTech bivalent COVID only |
|
flu alone | influenza vaccine of any type only |
|
Recruiting Locations
More Details
- NCT ID
- NCT05858450
- Status
- Completed
- Sponsor
- Pfizer